A recent analysis by healthcare innovation expert Jesse Pines, MD, examines whether the Galleri multi-cancer early detection (MCED) blood test lives up to its promise.
Marketed as a simple blood draw capable of detecting over 50 cancers, Galleri analyzes cell-free DNA methylation patterns to identify a “cancer signal” and predict likely tissue of origin. The appeal is obvious: early detection without invasive screening.
But the current evidence tells a more nuanced story.